Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation. Issue 11 (14th August 2020)

• Record Type: Journal Article
• Authors: Hong, Haiyu; Liao, Shumin; Chen, Fenghong; Yang, Qintai; Wang, De‐Yun
• Is Part Of: Allergy. Volume 75:Issue 11(2020)
• Page Start: 2794
• Page End: 2804
• Publication Date: 2020-08-14
• Subjects: IL‐25 -- IL‐33 -- TSLP -- type 2 inflammation -- united airway disease; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.14526
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Under the concept of "united airway diseases, " the airway is a single organ wherein upper and lower airway diseases are commonly comorbid. The upper and lower airways are lined with respiratory epithelium that plays a vital role in immune surveillance and modulation as the first line of defense to various infective pathogens, allergens, and physical insults. Recently, there is a common hypothesis emphasizing epithelium‐derived cytokines, namely IL‐25, IL‐33, and TSLP, as key regulatory factors that link in immune‐pathogenic mechanisms of allergic rhinitis (AR), chronic rhinosinusitis (CRS), and asthma, mainly involving in type 2 inflammatory responses and linking innate and adaptive immunities. Herein, we review studies that elucidated the role of epithelium‐derived triple cytokines in both upper and lower airways with the purpose of expediting better clinical treatments and managements of AR, CRS, asthma, and other associated allergic diseases via applications of the modulators of these cytokines.